Identification of Neuregulin 1 as Predictor Outcome in Intracranial Astrocytoma

Ridha Dharmajaya; Abdurrahman Mouza

doi:10.3889/oamjms.2021.6338

Authors

Ridha Dharmajaya Department of Neurosurgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0001-8824-7726
Abdurrahman Mouza Department of Neurosurgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0003-1308-3768

DOI:

https://doi.org/10.3889/oamjms.2021.6338

Keywords:

Astrocytoma, Neuregulin 1, Brain tumor

Abstract

BACKGROUND: Astrocytoma is the most common primary brain tumor. The combination of adhesion molecules, proteases, and cytokines that regulate their expression likely underlies tumor progression. The cytokine of neuregulin 1 (NRG1) has a role in progression and invasion of tumor cells by activating signal after binding its receptor.

AIM: To identification NRG1 expression with characteristic of intracranial astrocytoma patient is the purpose of this study.

METHODS: This study uses analytic method with retrospective study. It analyzed the association between NRG1 expressions in astrocytoma patients. The study included 32 samples which were admitted to Haji Adam Malik Hospital Medan from September 2016 to August 2018.

RESULTS: There was no significant association between NRG1 expression with age (p = 0.853) and gender (p = 0.565) of astrocytoma patients, while there was a significant association between NRG1 expression with cell proliferation (p = 0.00), WHO grading of astrocytoma (p = 0.00), and outcomes (p = 0.023). According to this study, the most common results are strong NRG1 expression has many cells proliferation in 10 (31.1%) patients, strong NRG1 expression with Grade IV astrocytoma found in 7 (21.9%) patients, and moderate NRG1 expression in live patient found in 7 (21.9%) patient.

CONCLUSION: There is significant association between NRG1 expression and cell proliferation, WHO grading of astrocytoma, and outcomes.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Winn HR. Low-grade glioma. In: Youmans and Winn Neurological Surgery. 7th ed. New York: Elsevier; 2017. p. 4396.

National Organization for Rare Disorders, Astrocytoma; 2015. Available from: https://www.rarediseases.org/rare-diseases/astrocytoma. [Last accessed on 2018 Aug 27].

American Brain Tumor Association, Glioblatoma and Malignan Astrocytoma; 2017.

Zhao W, Schachner M. Neureguline-1 enhances cell adhesion molecule L1 expression in human glioma cells and promotes their migration as a function of malignancy. J Neuropathol Exp Neurol. 2013;72(3):244-55. https://doi.org/10.1097/nen.0b013e3182863dc5 PMid:23399902 DOI: https://doi.org/10.1097/NEN.0b013e3182863dc5

Maiti AK, Ghosh K, Chatterjee U, Chakrobarti S, Chatterjee S. Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytoma. Neurol India. 2008;56(4):456-62. https://doi.org/10.4103/0028-3886.44827 PMid:19127042 DOI: https://doi.org/10.4103/0028-3886.44827

Forsyth PA, Swah EG, Scheithauer BW, O’Fallon JR, Layton DD, Katzmann JA. Supratentorial pilocytic astrocytoma. Cancer. 1993;72:1335-42. DOI: https://doi.org/10.1002/1097-0142(19930815)72:4<1335::AID-CNCR2820720431>3.0.CO;2-E

Ritch PS, Carroll SL, Sontheimer H. Neuregulin-1 enhances survival of human astrocytic glioma cells. Glia. 2005;51(3):217-28. https://doi.org/10.1002/glia.2019 PMid:15812817 DOI: https://doi.org/10.1002/glia.20197

Pan B, Wang R, Huang Y, Garfiel D, Chen H. HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma. Onco Targets Ther. 2015;8:1185-91. https://doi.org/10.2147/ott.s78116 PMid:26045672 DOI: https://doi.org/10.2147/OTT.S78116

Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: An analysis of histologic parameters. Am J Surg Pathol. 1997;21(12):1455-65. https://doi.org/10.1097/00000478-199712000-00008 PMid:9414189 DOI: https://doi.org/10.1097/00000478-199712000-00008

Douet V, Chang L, Pritchett A, Lee K, Keating B, Bartsch H, et al. Schizophrenia-risk variant rs6994992 in the neuregulin-1 gene on brain developmental trajectories in typically developing children. Transl Psychiatry. 2014;4(5):e392. https://doi.org/10.1038/tp.2014.41 PMid:24865593 DOI: https://doi.org/10.1038/tp.2014.41

Prevot V, Rio C, Cho GJ, Lomniczi A, Heger S, Neville CM, et al. Normal female sexual development requires neuregulin-erbB receptor signaling in hypothalamic astrocytes. J Neurosci. 2003;23(1):230-9. https://doi.org/10.1523/jneurosci.23-01-00230.2003 PMid:12514220 DOI: https://doi.org/10.1523/JNEUROSCI.23-01-00230.2003

Taylor SB, Markham JA, Taylor AR, Kanaskie BZ, Koenig JI. Sex-specific neuroendocrine and behavioral phenotypes in hypomorphic Type II neuregulin 1 rats. Behav Brain Res. 2011;224(2):223-32. https://doi.org/10.1016/j.bbr.2011.05.008 PMid:21620900 DOI: https://doi.org/10.1016/j.bbr.2011.05.008

Ritch PA, Carroll SL, Sontheimer H. Neuregulin 1 Enhances Motility and Migration of Astrocytic Glioma Cell. Alabama: National Institutes of Health Public Access; 2003. https://doi.org/10.1074/jbc.m213074200 DOI: https://doi.org/10.1074/jbc.M213074200

Wadugu B, Kuhn B. The role of neuregulin/ErbB2/Erbb4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol. 2012;302(11):H2139-47. https://doi.org/10.1152/ajpheart.00063.2012 PMid:22427524 DOI: https://doi.org/10.1152/ajpheart.00063.2012

Liu Y, Ford BD, Mann MA, Fischbach GD. Neuregulin-1 increases the proliferation of neuronal progenitors from embryonic neural stem cells. Dev Biol. 2005;283(2):437-45. https://doi.org/10.1016/j.ydbio.2005.04.038 PMid:15949792 DOI: https://doi.org/10.1016/j.ydbio.2005.04.038

Anvari K, Seilanian Toussi M, Shahidsales S, Motlagh F, Reza Ehsaee M, Afshari F. Treatment outcomes and prognostic factors in adult astrocytoma: In North East of Iran. Iran J Cancer Prev. 2016;9(4):e4099. https://doi.org/10.17795/ijcp-4099 PMid:27822343 DOI: https://doi.org/10.17795/ijcp-4099